Sciegen Pharms

JUL 1, 2026 · REGULATORY APPROVAL

FDA approval: Brivaracetam

U.S. Food and Drug Administration

FDA approval of a generic brivaracetam formulation; establishes regulatory authorization but does not report clinical trial data or comparative efficacy evidence.

JUN 25, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Naproxen Sodium (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for naproxen sodium labeling; describes a regulatory action, not clinical evidence of efficacy or safety.

JUN 17, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Fluoxetine (Manufacturing (CMC))

U.S. Food and Drug Administration

FDA supplemental approval for manufacturing changes to an established generic fluoxetine product; does not contain clinical efficacy or safety data.